Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review

[11] Singh P(2021)PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews BMJ 372 367-1084

[12] Korytowsky B(2013)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement Eur J Health Econ HEPAC Health Econ Prev Care 14 1075-S105

[13] Caranfa JT(2014)Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma J Vasc Interv Radiol 25 S104-408

[14] Miller JD(2014)Simulation study on cost-effectiveness of radioembolization compared with trans-arterial chemoembolization for hepatocellular carcinoma [abstract] J Vasc Interv Radiol 25 401-221

[15] Sill BE(2021)The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization Eur J Surg Oncol 47 209-S280

[16] Salem R(2018)Cost-effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma J Comp Eff Res 7 S279-v240

[17] Gordon AC(2015)Economic evaluation of glass yttrium-90 microspheres versus sorafenib for the treatment of advanced hepatocellular carcinoma: cost effectiveness analysis in the United Kingdom Cardiovasc Intervent Radiol 38 v239-344

[18] Mouli S(2017)Cost effectiveness of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma patients in the UK Ann Oncol 28 336-264

[19] Hickey R(2017)Real-world data for the evaluation of transarterial radioembolization versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis Value Health 20 532A–3A-1068

[20] Kallini J(2018)Cost-effectiveness of sorafenib versus selective internal radiation therapy for patients with advanced hepatocellular carcinoma Hepatology 68 1-e277

[11] Singh P(2021)PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews BMJ 372 367-1084

[12] Korytowsky B(2013)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement Eur J Health Econ HEPAC Health Econ Prev Care 14 1075-S105

[13] Caranfa JT(2014)Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma J Vasc Interv Radiol 25 S104-408

[14] Miller JD(2014)Simulation study on cost-effectiveness of radioembolization compared with trans-arterial chemoembolization for hepatocellular carcinoma [abstract] J Vasc Interv Radiol 25 401-221

[15] Sill BE(2021)The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization Eur J Surg Oncol 47 209-S280

[16] Salem R(2018)Cost-effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma J Comp Eff Res 7 S279-v240

[17] Gordon AC(2015)Economic evaluation of glass yttrium-90 microspheres versus sorafenib for the treatment of advanced hepatocellular carcinoma: cost effectiveness analysis in the United Kingdom Cardiovasc Intervent Radiol 38 v239-344

[18] Mouli S(2017)Cost effectiveness of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma patients in the UK Ann Oncol 28 336-264

[19] Hickey R(2017)Real-world data for the evaluation of transarterial radioembolization versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis Value Health 20 532A–3A-1068

[20] Kallini J(2018)Cost-effectiveness of sorafenib versus selective internal radiation therapy for patients with advanced hepatocellular carcinoma Hepatology 68 1-e277